AM26257PU-N Complement C5 antibody

See related secondary antibodies

Search for all "Complement C5"

0.1 mg / $390.00
Delivery Time: 7-10 working days*
(*) valid for US customers only

Quick Overview

Mouse anti Human Complement C5 2952

AM26257PU-N

Product Description for Complement C5

Mouse anti Human Complement C5 2952.
Presentation: Purified
Product is tested for Paraffin Sections, Frozen Sections, Western blot / Immunoblot, Enzyme Immunoassay, Functional assay.

Properties for Complement C5

Product Category Primary Antibodies
Target Category
Quantity 0.1 mg
Synonyms C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4, CPAMD4, Complement component 5
Presentation Purified
Reactivity Hu
Applications C, E, FN, P, WB
Clonality Monoclonal
Clone 2952
Host Mouse
Isotype IgG1
Shipping to Worldwide
PDF datasheet View Datasheet
Manufacturer OriGene Technologies GmbH
Material safety datasheet MSDS for Monoclonal Antibodies (de)

Datasheet Extract

Immunogen
Swiss Prot Num:
P01031
GeneID:
727
Isotype control AM03095PU-N, SM10P (for use in human samples)
Application Immunohistochemistry on frozen sections: The typical starting working dilution is 1:50.
Immunohistochemistry on paraffin sections: The typical starting working dilution is 1:50.
Functional assays.
Immunoassays.
Western blot: The typical starting working dilution is 1:50.
Background C5 is involved in the activation of the lythic pathway within the complement system which is an important factor in innate immunity. The complement pathways can be divided in the activation pathways and lytic pathway. The activation pathways lead via C3 to the cleavage of the fifth complement component C5. C5a induces smooth muscle contraction, increases vascular permeability, causes degranulation of mast cells and basophils, and release of lysosomal enzymes. In addition C5a stimulates the directed migration of neutrophils, eosinophils, basophils and monocytes. Recent studies indicate the modulation of the acute-phase response in liver and an overall immune response by inducing synthesis of cytokines such as TNF-alpha IL-1beta, IL-6 and IL-8.
Concentration 0.1 mg/ml
General Readings
  1. Nozaki M, Raisler BJ, Sakurai E, Sarma JV, Barnum SR, Lambris JD, et al. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2328-33. Epub 2006 Feb 1. PubMed PMID: 16452172. (Free PMC Article available, 6 images available)
Storage

Store at 2 - 8 °C.
Shelf life: one year from despatch.

Format
Purification:
Protein G
Buffer System:
PBS
Stabilizers:
0.1% bovine serum albumin
State:
Liquid 0.2 µm filtered Ig fraction
Purified
Species Reactivity
Species reactivity (tested):
Human
Specificity
Specificity:
Monoclonal antibody 2952 reacts with a neo-epitope on C5a (des-Arg) that is formed upon cleavage of C5 into C5a and C5b.

Accessory Products

Proteins and/or Positive Controls

Proteins for Complement C5 (2 products)

Catalog No. Species Pres. Purity   Source  

Complement C5a

Complement C5a Human Purified > 98 % pure by SDS-PAGE gel and HPLC analyses E. coli
  OriGene Technologies GmbH

Complement C5a

Complement C5a Human Purified > 98 % pure by SDS-PAGE gel and HPLC analyses E. coli
  OriGene Technologies GmbH

Positive controls for Complement C5 (1 products)

Catalog No. Species Pres. Purity   Source  

C5 overexpression lysate

C5 overexpression lysate
0.1 mg / $495.00
  OriGene Technologies, Inc.
  • LinkedIn